Tajikistan Pharmaceutical Industry Program 2026-2030: Localization Outlook

1. Key takeaways

Tajikistan is moving localization of the pharmaceutical industry from policy statements to the planning level. On May 28, 2026, a government meeting chaired by President Emomali Rahmon reviewed the draft Program for the Development of the Pharmaceutical Industry for 2026 to 2030, with a report delivered by Jamoliddin Abdullozoda, Minister of Health and Social Protection. The publicly disclosed directions include import substitution, meeting domestic demand with domestic medical products, cultivation and processing of medicinal plants, and attracting foreign investment. GRZAN highlights two points. First, as of the verification date the program remains a draft under consideration: no approved official text of its specific targets, timetable or supporting measures has been located, and this article cites no quantitative goals. Second, the legislative basis for local production support in law comes from Article 4(5) of Law No. 1893 — the state provides state support for domestic production of medicines and medical products — a provision in force since 2022 and the legislative foundation of the program rather than a product of it.

2. Legal basis

3. Expert insights

Insight 1: Article 4(5) and Article 6(1)(2) form a two-layer legal basis for local production support. Article 4(5) stands in the general provisions and establishes the principle of state support for domestic production; Article 6(1)(2) lists support for domestic production of medicines and medical products as one of the ten methods of state regulation. The program is a policy implementation tool, while the legal basis has existed since 2022, and companies assessing policy risk should distinguish between the two levels.

Insight 2: Article 1(25) sets a quality threshold for localization. The definition of contract production requires conformity with good manufacturing practice and international standards for medical products. The implication is that localization is not substitution at a lower standard; localized production must still meet GMP and international standard requirements. This point is particularly critical for Chinese manufacturers considering establishing a plant in Tajikistan.

Insight 3: Article 6(1)(10) lists producer accreditation as a method of state regulation, providing a qualification channel for localized entities. The Russian wording of this method refers to accreditation of producers; its implementing procedure must be confirmed separately. As of the verification date, no current specific arrangement beyond the enabling procedure of Law No. 1893 has been located, and it is not cited here as an operational step.

Insight 4: the foreign standard recognition power of Article 8(17) provides a bridging channel for foreign investment in technical standards. The Ministry of Health recognizes foreign pharmacopoeias and quality standards where necessary, which means that the existing standard systems of foreign-invested enterprises may be adopted, but only on a case-by-case recognition basis.

Insight 5: the simplified registration channel of Article 17(9) complements localization. The paragraph targets states of emergency, outbreaks of infectious diseases and the prevention and treatment of diseases caused by special factors, and allows a simplified procedure determined by the Ministry of Health in agreement with the supervisory authority. For enterprises with emergency supply capability this is a route worth watching, but the specific product scope and procedure are subject to the text published by the Ministry of Health.

Insight 6: the program is at the draft stage, and quantitative targets cannot yet be cited. As of the verification date, what public channels confirm is the fact of deliberation and the directional statements; no official text of specific indicators, timetables, or supporting measures on tax and land has been located, and GRZAN does not accept any figure without a stated source.

4. Practical recommendations

1. Distinguish the binding force of the legislative basis from the policy draft. Under Article 4(5) and Article 6(1)(2), support for local production already has a legislative basis; the specific provisions of the 2026 to 2030 program await publication of the official text.
2. Treat GMP and international standards as the precondition for localization. Under Article 1(25), any localization or contract production arrangement must be designed to GMP and international standards.
3. Track publication of the official program text. Establish a periodic search mechanism for official government and Ministry of Health channels and assess the impact promptly after the official text is published.
4. Assess the possible application of foreign standard recognition. Under Article 8(17), approach the Ministry of Health on the recognition of existing standard systems and proceed case by case.
5. Watch the applicable scenarios of the simplified registration channel. Under Article 17(9), emergency and special prevention scenarios leave room for simplified registration, with procedures subject to the text of the Ministry of Health.
6. Remain prudent about market background data. Data on import dependence and health expenditure vary in caliber across sources and constitute a practical estimate, for internal judgment only.

5. Verification checklist

• □ Confirmed that the government meeting of May 28, 2026 reviewed the draft Program for the Development of the Pharmaceutical Industry for 2026 to 2030
• □ Confirmed that Article 4(5) and Article 6(1)(2) form the legislative basis for local production support
• □ Confirmed that Article 1(25) requires contract production to meet GMP and international standards for medical products
• □ Confirmed that no official text of the quantitative targets of the program exists and none were cited
• □ Established a periodic search mechanism for official government and Ministry of Health channels
• □ Approached the Ministry of Health on foreign standard recognition case by case (Article 8(17))
• □ Labeled market background data as a practical estimate and did not cite them as regulatory conclusions

Regulatory information verified as of October 29, 2026.

In the Central Asia market, the core capabilities of GRZAN concentrate on three points. First, distinguishing the different legal positions of individual markets within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states, where a national pathway and a Union pathway both exist; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services, which may act as the statutory representative of manufacturers in these countries and assume registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com